Adverts

Open Access Articles- Top Results for 2CBCB-NBOMe

2CBCB-NBOMe

</th></tr>
2CBCB-NBOMe
File:2CBCB-NBOMe-skeletal.svg
Systematic (IUPAC) name
N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
Clinical data
  • Uncontrolled
Identifiers
1354634-09-5 7pxN
ChemSpider 26234935 7pxY
Chemical data
Formula C19H22BrNO3
392.286 g/mol
 14pxN (what is this?)  (verify)

2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2007 at Purdue University as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT2A and 5-HT2C receptors, with a Ki of 0.27nM at the human 5-HT2A receptor, a similar potency to other agonists such as TCB-2, NBOMe-2C-I and Bromo-DragonFLY.[1]

See also

References

  1. ^ Braden, Michael Robert (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.